

**Retina World Congress
Global Gene Therapy for Retinal Diseases
November 21, 2021
Live Webinar**

Target Audience

This activity is designed to meet the needs of retina specialists, comprehensive ophthalmologists, retina fellows and residents, and healthcare providers who are interested in applying the most recent advancements in the retinal medicine field, including emerging techniques for imaging and treatments for retinal and vitreoretinal diseases.

Learning Objectives

Upon completion of the educational activity, participants should be able to:

- Describe how clinical trial results differentiate treatments based on functional, anatomic, and visual outcomes
- Evaluate innovative therapies and delivery systems based on their ability to improve durability and maintain visual outcomes
- Identify patients who would be suitable candidates for gene-replacement therapy

Criteria for Success

Certificates of completion will be awarded based on the participant's attendance and submission of the activity evaluation/claim credit form at <https://ivista.digitellinc.com/ivista/live/142/page/862>. **Please claim your credit by December 15, 2021.**

You must participate in the entire activity to receive credit. There is no fee to participate in this activity. If you have questions about this activity, please contact AKH Inc. at JGoldman@akhcme.com.



CE credit provided by AKH Inc., Advancing Knowledge in Healthcare.



JOINTLY ACCREDITED PROVIDER™
INTERPROFESSIONAL CONTINUING EDUCATION

In support of improving patient care, this activity has been planned and implemented by AKH Inc., Advancing Knowledge in Healthcare and iVista Medical Education, Inc. AKH Inc., Advancing Knowledge in Healthcare is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physicians

AKH Inc., Advancing Knowledge in Healthcare designates this live activity for a maximum of 1.5 *AMA PRA Category 1 Credit(s)*™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Commercial Support

This activity is supported by educational grants from Alcon Vision, LLC, Novartis, Regeneron Pharmaceuticals, and RegenexBio.

Disclosures

It is the policy of AKH Inc. to ensure independence, balance, objectivity, scientific rigor, and integrity in all of its continuing education activities. The author must disclose to the participants any significant relationships with ineligible companies whose products or devices may be mentioned in the activity or with the commercial supporter of this continuing education activity. Identified conflicts of interest are mitigated by AKH prior to accreditation of the activity. AKH planners and reviewers have no relevant financial relationships to disclose.

DISCLOSURES		
Name	Relationship	Commercial Interest
Mark Barakat, MD (faculty)	Consultant	Adverum Biotechnologies; Alcon; Allegro; Allergan; Alimera; Bausch and Lomb; Clearside Biomedical; EyePoint Pharmaceuticals; Kodiak Sciences; Genentech; Graybug; Novartis; Palatin Technologies; Ocular Therapeutix; RegenxBio
	Speaker	Novartis Regeneron
Tarek Hassan, MD (faculty)	N/A	Nothing to disclose
Jeffrey Heier, MD (faculty)	Advisor	2020 Onsite; 4DMT; Abpro; Adverum; Aerie; Affamed; Allegro; Allergan; Allgenesis; American Genomics; Annexon; Apellis; Aprea; Asclepix; Aviceda; Biovisics; BVT; DTx; Gemini; Genentech/Roche; Graybug; Gyroscope; iRenix; Iveric; Johnson & Johnson; Kanghong; NGM; Notal Vision; Novartis; Ocular Therapeutix; Ocuphire; OcuTerra; Oriole; Oxurion; Palatin; Regeneron; Regenxbio; RetinAI; Retrotope; Santen; Scifluor; Stealth Biotherapeutics; Surrozen; Thea; Unity Bio; Verseon
Peter K. Kaiser, MD (faculty)	Consultant	Aerie; Aerpio; Alcon; Allegro; Allergan; Annexon; Biosciences; AsclepiX; Bayer; Bausch and Lomb; Biogen Idec; Boerenger Ingelheim; Carl Zeiss Meditec; Clearside Biomedical; Eyevensys; Formycon/BioEq; GmbH; Galecto Biotech; Galimedix; Glaukos; iRenix; jCyte; Kala Pharmaceuticals; Kanghong; Kodiak; NGM; Biopharmaceuticals, Inc.; Novartis; Ocugenix; Oculis; Omeros; Opthea; Oxurion (Thrombogenics); Regeneron; RegenxBio; Retinal Sciences; Roivant; Santen; SciFluor; Shire; Spark; Stealth Biotherapeutics; Takeda; Verena (Digisight)
	Contracted Researcher	Stealth
Arshad Khanani, MD, MA (faculty)	Advisor; Consultant; Researcher	Adverum; Regenxbio
Aleksandra Rachitskaya, MD (faculty)	Consultant	Alcon; Genentech; Novartis; Regeneron; Zeiss
Jorge Rocha, MD, PhD (faculty)	N/A	Nothing to disclose
Dorothy Caputo, MA, BSN, RN, Vice President of Continuing Education & Compliance	N/A	Nothing to disclose
AKH Staff and Planners	N/A	Nothing to disclose
iVista Staff and Planners	N/A	Nothing to disclose
All of the relevant financial relationships listed for these individuals have been mitigated.		

Disclaimer

This course is designed solely to provide the healthcare professional with information to assist in his/her practice and professional development and is not to be considered a diagnostic tool to replace professional advice or treatment. The course serves as a general guide to the healthcare professional, and therefore, cannot be considered as giving legal, nursing, medical, or other professional advice in specific cases. AKH Inc. specifically disclaim responsibility for any adverse consequences resulting directly or indirectly from information in the course, for undetected error, or through participant's misunderstanding of the content.

Disclosure of Unlabeled Use and Investigational Product

This educational activity may include discussion of uses of agents that are investigational and/or unapproved by the FDA. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.